id	sid	tid	token	lemma	pos
dpc-4390	1	1	dermatology	dermatology	NOUN
dpc-4390	1	2	:	:	PUNCT
dpc-4390	1	3	practical	practical	ADJ
dpc-4390	1	4	and	and	CCONJ
dpc-4390	1	5	conceptual	conceptual	ADJ
dpc-4390	1	6	research	research	NOUN
dpc-4390	1	7	letter	letter	NOUN
dpc-4390	2	1	|	|	ADV
dpc-4390	2	2	dermatol	dermatol	ADJ
dpc-4390	2	3	pract	pract	NOUN
dpc-4390	2	4	concept	concept	NOUN
dpc-4390	2	5	.	.	PUNCT
dpc-4390	3	1	2024;14(4):e2024259	2024;14(4):e2024259	NUM
dpc-4390	3	2	1	1	NUM
dpc-4390	3	3	impact	impact	NOUN
dpc-4390	3	4	of	of	ADP
dpc-4390	3	5	xerosis	xerosis	NOUN
dpc-4390	3	6	in	in	ADP
dpc-4390	3	7	patients	patient	NOUN
dpc-4390	3	8	with	with	ADP
dpc-4390	3	9	cancer	cancer	NOUN
dpc-4390	3	10	receiving	receive	VERB
dpc-4390	3	11	epidermal	epidermal	ADJ
dpc-4390	3	12	growth	growth	NOUN
dpc-4390	3	13	factor	factor	NOUN
dpc-4390	3	14	receptor	receptor	NOUN
dpc-4390	3	15	or	or	CCONJ
dpc-4390	3	16	mitogen	mitogen	NOUN
dpc-4390	3	17	-	-	PUNCT
dpc-4390	3	18	activated	activate	VERB
dpc-4390	3	19	protein	protein	NOUN
dpc-4390	3	20	kinase	kinase	NOUN
dpc-4390	3	21	inhibitors	inhibitor	NOUN
dpc-4390	3	22	:	:	PUNCT
dpc-4390	3	23	atixi	atixi	NOUN
dpc-4390	3	24	,	,	PUNCT
dpc-4390	3	25	a	a	DET
dpc-4390	3	26	non	non	ADJ
dpc-4390	3	27	-	-	ADJ
dpc-4390	3	28	interventional	interventional	ADJ
dpc-4390	3	29	prospective	prospective	ADJ
dpc-4390	3	30	pilot	pilot	NOUN
dpc-4390	3	31	study	study	NOUN
dpc-4390	3	32	pietro	pietro	PROPN
dpc-4390	3	33	quaglino1	quaglino1	PROPN
dpc-4390	3	34	,	,	PUNCT
dpc-4390	3	35	giuseppe	giuseppe	PROPN
dpc-4390	3	36	argenziano2	argenziano2	PROPN
dpc-4390	3	37	,	,	PUNCT
dpc-4390	3	38	emi	emi	PROPN
dpc-4390	3	39	dika3,4	dika3,4	PROPN
dpc-4390	3	40	,	,	PUNCT
dpc-4390	3	41	michela	michela	PROPN
dpc-4390	3	42	starace4,5	starace4,5	PROPN
dpc-4390	3	43	,	,	PUNCT
dpc-4390	3	44	simone	simone	PROPN
dpc-4390	3	45	amabile1	amabile1	PROPN
dpc-4390	3	46	,	,	PUNCT
dpc-4390	3	47	paolo	paolo	PROPN
dpc-4390	3	48	fava1	fava1	PROPN
dpc-4390	3	49	,	,	PUNCT
dpc-4390	3	50	elvira	elvira	PROPN
dpc-4390	3	51	moscarella2	moscarella2	PROPN
dpc-4390	3	52	,	,	PUNCT
dpc-4390	3	53	bianca	bianca	PROPN
dpc-4390	3	54	maria	maria	PROPN
dpc-4390	3	55	piraccini4,5	piraccini4,5	PROPN
dpc-4390	3	56	,	,	PUNCT
dpc-4390	3	57	alain	alain	PROPN
dpc-4390	3	58	delarue6	delarue6	PROPN
dpc-4390	3	59	,	,	PUNCT
dpc-4390	3	60	olivia	olivia	PROPN
dpc-4390	3	61	dialla7	dialla7	PROPN
dpc-4390	3	62	,	,	PUNCT
dpc-4390	3	63	fabienne	fabienne	PROPN
dpc-4390	3	64	zumaglini6	zumaglini6	PROPN
dpc-4390	3	65	,	,	PUNCT
dpc-4390	3	66	giampiero	giampiero	PROPN
dpc-4390	3	67	girolomoni8	girolomoni8	PROPN
dpc-4390	3	68	1	1	NUM
dpc-4390	3	69	dermatologic	dermatologic	ADJ
dpc-4390	3	70	clinic	clinic	NOUN
dpc-4390	3	71	,	,	PUNCT
dpc-4390	3	72	department	department	NOUN
dpc-4390	3	73	of	of	ADP
dpc-4390	3	74	medical	medical	ADJ
dpc-4390	3	75	sciences	sciences	PROPN
dpc-4390	3	76	,	,	PUNCT
dpc-4390	3	77	university	university	PROPN
dpc-4390	3	78	of	of	ADP
dpc-4390	3	79	turin	turin	PROPN
dpc-4390	3	80	,	,	PUNCT
dpc-4390	3	81	turin	turin	PROPN
dpc-4390	3	82	,	,	PUNCT
dpc-4390	3	83	italy	italy	PROPN
dpc-4390	3	84	2	2	NUM
dpc-4390	3	85	dermatology	dermatology	NOUN
dpc-4390	3	86	unit	unit	NOUN
dpc-4390	3	87	,	,	PUNCT
dpc-4390	3	88	department	department	NOUN
dpc-4390	3	89	of	of	ADP
dpc-4390	3	90	mental	mental	ADJ
dpc-4390	3	91	and	and	CCONJ
dpc-4390	3	92	physical	physical	ADJ
dpc-4390	3	93	health	health	NOUN
dpc-4390	3	94	and	and	CCONJ
dpc-4390	3	95	preventive	preventive	ADJ
dpc-4390	3	96	medicine	medicine	NOUN
dpc-4390	3	97	,	,	PUNCT
dpc-4390	3	98	university	university	PROPN
dpc-4390	3	99	of	of	ADP
dpc-4390	3	100	campania	campania	PROPN
dpc-4390	3	101	luigi	luigi	PROPN
dpc-4390	3	102	vanvitelli	vanvitelli	PROPN
dpc-4390	3	103	naples	naples	PROPN
dpc-4390	3	104	,	,	PUNCT
dpc-4390	3	105	italy	italy	PROPN
dpc-4390	3	106	3	3	NUM
dpc-4390	3	107	oncologic	oncologic	PROPN
dpc-4390	3	108	dermatology	dermatology	NOUN
dpc-4390	3	109	unit	unit	NOUN
dpc-4390	3	110	,	,	PUNCT
dpc-4390	3	111	irccs	irccs	PROPN
dpc-4390	3	112	azienda	azienda	PROPN
dpc-4390	3	113	ospedaliero	ospedaliero	PROPN
dpc-4390	3	114	-	-	PUNCT
dpc-4390	3	115	universitaria	universitaria	PROPN
dpc-4390	3	116	di	di	PROPN
dpc-4390	3	117	bologna	bologna	PROPN
dpc-4390	3	118	,	,	PUNCT
dpc-4390	3	119	italy	italy	PROPN
dpc-4390	3	120	4	4	NUM
dpc-4390	3	121	department	department	PROPN
dpc-4390	3	122	of	of	ADP
dpc-4390	3	123	medical	medical	ADJ
dpc-4390	3	124	and	and	CCONJ
dpc-4390	3	125	surgical	surgical	ADJ
dpc-4390	3	126	sciences	science	NOUN
dpc-4390	3	127	,	,	PUNCT
dpc-4390	3	128	alma	alma	NOUN
dpc-4390	3	129	mater	mater	PROPN
dpc-4390	3	130	studiorum	studiorum	PROPN
dpc-4390	3	131	university	university	PROPN
dpc-4390	3	132	of	of	ADP
dpc-4390	3	133	bologna	bologna	PROPN
dpc-4390	3	134	,	,	PUNCT
dpc-4390	3	135	italy	italy	PROPN
dpc-4390	3	136	5	5	NUM
dpc-4390	3	137	dermatology	dermatology	NOUN
dpc-4390	3	138	unit	unit	NOUN
dpc-4390	3	139	,	,	PUNCT
dpc-4390	3	140	irccs	irccs	PROPN
dpc-4390	3	141	azienda	azienda	PROPN
dpc-4390	3	142	ospedaliero	ospedaliero	PROPN
dpc-4390	3	143	-	-	PUNCT
dpc-4390	3	144	universitaria	universitaria	PROPN
dpc-4390	3	145	di	di	PROPN
dpc-4390	3	146	bologna	bologna	PROPN
dpc-4390	3	147	,	,	PUNCT
dpc-4390	3	148	policlinico	policlinico	PROPN
dpc-4390	3	149	s.	s.	PROPN
dpc-4390	3	150	orsola	orsola	PROPN
dpc-4390	3	151	-	-	PUNCT
dpc-4390	3	152	malpighi	malpighi	PROPN
dpc-4390	3	153	,	,	PUNCT
dpc-4390	3	154	bologna	bologna	PROPN
dpc-4390	3	155	,	,	PUNCT
dpc-4390	3	156	italy	italy	PROPN
dpc-4390	3	157	6	6	NUM
dpc-4390	3	158	pierre	pierre	PROPN
dpc-4390	3	159	fabre	fabre	PROPN
dpc-4390	3	160	,	,	PUNCT
dpc-4390	3	161	lavaur	lavaur	NOUN
dpc-4390	3	162	,	,	PUNCT
dpc-4390	3	163	france	france	PROPN
dpc-4390	3	164	7	7	NUM
dpc-4390	3	165	pierre	pierre	PROPN
dpc-4390	3	166	fabre	fabre	PROPN
dpc-4390	3	167	,	,	PUNCT
dpc-4390	3	168	boulogne	boulogne	PROPN
dpc-4390	3	169	-	-	NOUN
dpc-4390	3	170	billancourt	billancourt	PROPN
dpc-4390	3	171	,	,	PUNCT
dpc-4390	3	172	france	france	PROPN
dpc-4390	3	173	8	8	NUM
dpc-4390	3	174	department	department	NOUN
dpc-4390	3	175	of	of	ADP
dpc-4390	3	176	medicine	medicine	NOUN
dpc-4390	3	177	,	,	PUNCT
dpc-4390	3	178	section	section	NOUN
dpc-4390	3	179	of	of	ADP
dpc-4390	3	180	dermatology	dermatology	NOUN
dpc-4390	3	181	,	,	PUNCT
dpc-4390	3	182	university	university	NOUN
dpc-4390	3	183	of	of	ADP
dpc-4390	3	184	verona	verona	PROPN
dpc-4390	3	185	,	,	PUNCT
dpc-4390	3	186	italy	italy	PROPN
dpc-4390	3	187	key	key	ADJ
dpc-4390	3	188	words	word	NOUN
dpc-4390	3	189	:	:	PUNCT
dpc-4390	3	190	adverse	adverse	ADJ
dpc-4390	3	191	effects	effect	NOUN
dpc-4390	3	192	,	,	PUNCT
dpc-4390	3	193	anti	anti	ADJ
dpc-4390	3	194	-	-	ADJ
dpc-4390	3	195	cancer	cancer	ADJ
dpc-4390	3	196	treatments	treatment	NOUN
dpc-4390	3	197	,	,	PUNCT
dpc-4390	3	198	cutaneous	cutaneous	ADJ
dpc-4390	3	199	toxicity	toxicity	NOUN
dpc-4390	3	200	,	,	PUNCT
dpc-4390	3	201	egfr	egfr	ADJ
dpc-4390	3	202	inhibitors	inhibitor	NOUN
dpc-4390	3	203	,	,	PUNCT
dpc-4390	3	204	mek	mek	PROPN
dpc-4390	3	205	inhibitors	inhibitor	NOUN
dpc-4390	3	206	,	,	PUNCT
dpc-4390	3	207	xerosis	xerosis	NOUN
dpc-4390	3	208	citation	citation	NOUN
dpc-4390	3	209	:	:	PUNCT
dpc-4390	3	210	quaglino	quaglino	PROPN
dpc-4390	3	211	p	p	X
dpc-4390	3	212	,	,	PUNCT
dpc-4390	3	213	argenziano	argenziano	ADJ
dpc-4390	3	214	g	g	NOUN
dpc-4390	3	215	,	,	PUNCT
dpc-4390	3	216	dika	dika	X
dpc-4390	3	217	e	e	NOUN
dpc-4390	3	218	,	,	PUNCT
dpc-4390	3	219	et	et	PROPN
dpc-4390	3	220	al	al	PROPN
dpc-4390	3	221	.	.	PROPN
dpc-4390	3	222	impact	impact	NOUN
dpc-4390	3	223	of	of	ADP
dpc-4390	3	224	xerosis	xerosis	NOUN
dpc-4390	3	225	in	in	ADP
dpc-4390	3	226	patients	patient	NOUN
dpc-4390	3	227	with	with	ADP
dpc-4390	3	228	cancer	cancer	NOUN
dpc-4390	3	229	receiving	receive	VERB
dpc-4390	3	230	epidermal	epidermal	ADJ
dpc-4390	3	231	growth	growth	NOUN
dpc-4390	3	232	factor	factor	NOUN
dpc-4390	3	233	receptor	receptor	NOUN
dpc-4390	3	234	or	or	CCONJ
dpc-4390	3	235	mitogen	mitogen	NOUN
dpc-4390	3	236	-	-	PUNCT
dpc-4390	3	237	activated	activate	VERB
dpc-4390	3	238	protein	protein	NOUN
dpc-4390	3	239	kinase	kinase	NOUN
dpc-4390	3	240	inhibitors	inhibitor	NOUN
dpc-4390	3	241	:	:	PUNCT
dpc-4390	3	242	atixi	atixi	NOUN
dpc-4390	3	243	,	,	PUNCT
dpc-4390	3	244	a	a	DET
dpc-4390	3	245	non	non	ADJ
dpc-4390	3	246	-	-	ADJ
dpc-4390	3	247	interventional	interventional	ADJ
dpc-4390	3	248	,	,	PUNCT
dpc-4390	3	249	prospective	prospective	ADJ
dpc-4390	3	250	,	,	PUNCT
dpc-4390	3	251	pilot	pilot	NOUN
dpc-4390	3	252	study	study	NOUN
dpc-4390	3	253	.	.	PUNCT
dpc-4390	4	1	dermatol	dermatol	NOUN
dpc-4390	4	2	pract	pract	PROPN
dpc-4390	4	3	concept	concept	NOUN
dpc-4390	4	4	.	.	PUNCT
dpc-4390	5	1	2024;14(4):e2024259	2024;14(4):e2024259	X
dpc-4390	5	2	.	.	PUNCT
dpc-4390	5	3	doi	doi	PROPN
dpc-4390	5	4	:	:	PUNCT
dpc-4390	5	5	https://doi.org/10.5826/dpc.1404a259	https://doi.org/10.5826/dpc.1404a259	NOUN
dpc-4390	5	6	accepted	accept	VERB
dpc-4390	5	7	:	:	PUNCT
dpc-4390	5	8	may	may	AUX
dpc-4390	5	9	28	28	NUM
dpc-4390	5	10	,	,	PUNCT
dpc-4390	5	11	2024	2024	NUM
dpc-4390	5	12	;	;	PUNCT
dpc-4390	5	13	published	publish	VERB
dpc-4390	5	14	:	:	PUNCT
dpc-4390	5	15	october	october	PROPN
dpc-4390	5	16	2024	2024	NUM
dpc-4390	5	17	copyright	copyright	NOUN
dpc-4390	5	18	:	:	PUNCT
dpc-4390	6	1	©	©	PROPN
dpc-4390	6	2	2024	2024	NUM
dpc-4390	6	3	quaglino	quaglino	NOUN
dpc-4390	6	4	et	et	PROPN
dpc-4390	6	5	al	al	PROPN
dpc-4390	6	6	.	.	PUNCT
dpc-4390	7	1	this	this	PRON
dpc-4390	7	2	is	be	AUX
dpc-4390	7	3	an	an	DET
dpc-4390	7	4	open	open	ADJ
dpc-4390	7	5	-	-	PUNCT
dpc-4390	7	6	access	access	NOUN
dpc-4390	7	7	article	article	NOUN
dpc-4390	7	8	distributed	distribute	VERB
dpc-4390	7	9	under	under	ADP
dpc-4390	7	10	the	the	DET
dpc-4390	7	11	terms	term	NOUN
dpc-4390	7	12	of	of	ADP
dpc-4390	7	13	the	the	DET
dpc-4390	7	14	creative	creative	ADJ
dpc-4390	7	15	commons	common	NOUN
dpc-4390	7	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-4390	7	17	license	license	NOUN
dpc-4390	7	18	(	(	PUNCT
dpc-4390	7	19	by	by	ADP
dpc-4390	7	20	-	-	PUNCT
dpc-4390	7	21	nc-4.0	nc-4.0	NOUN
dpc-4390	7	22	)	)	PUNCT
dpc-4390	7	23	,	,	PUNCT
dpc-4390	7	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-4390	7	25	,	,	PUNCT
dpc-4390	7	26	which	which	PRON
dpc-4390	7	27	permits	permit	VERB
dpc-4390	7	28	unrestricted	unrestricted	ADJ
dpc-4390	7	29	noncommercial	noncommercial	ADJ
dpc-4390	7	30	use	use	NOUN
dpc-4390	7	31	,	,	PUNCT
dpc-4390	7	32	distribution	distribution	NOUN
dpc-4390	7	33	,	,	PUNCT
dpc-4390	7	34	and	and	CCONJ
dpc-4390	7	35	reproduction	reproduction	NOUN
dpc-4390	7	36	in	in	ADP
dpc-4390	7	37	any	any	DET
dpc-4390	7	38	medium	medium	NOUN
dpc-4390	7	39	,	,	PUNCT
dpc-4390	7	40	provided	provide	VERB
dpc-4390	7	41	the	the	DET
dpc-4390	7	42	original	original	ADJ
dpc-4390	7	43	authors	author	NOUN
dpc-4390	7	44	and	and	CCONJ
dpc-4390	7	45	source	source	NOUN
dpc-4390	7	46	are	be	AUX
dpc-4390	7	47	credited	credit	VERB
dpc-4390	7	48	.	.	PUNCT
dpc-4390	8	1	funding	funding	NOUN
dpc-4390	8	2	:	:	PUNCT
dpc-4390	8	3	this	this	DET
dpc-4390	8	4	study	study	NOUN
dpc-4390	8	5	and	and	CCONJ
dpc-4390	8	6	its	its	PRON
dpc-4390	8	7	related	related	ADJ
dpc-4390	8	8	cost	cost	NOUN
dpc-4390	8	9	and	and	CCONJ
dpc-4390	8	10	fees	fee	NOUN
dpc-4390	8	11	,	,	PUNCT
dpc-4390	8	12	medical	medical	ADJ
dpc-4390	8	13	writing	writing	NOUN
dpc-4390	8	14	assistance	assistance	NOUN
dpc-4390	8	15	for	for	ADP
dpc-4390	8	16	the	the	DET
dpc-4390	8	17	preparation	preparation	NOUN
dpc-4390	8	18	of	of	ADP
dpc-4390	8	19	this	this	DET
dpc-4390	8	20	manuscript	manuscript	NOUN
dpc-4390	8	21	and	and	CCONJ
dpc-4390	8	22	the	the	DET
dpc-4390	8	23	open	open	ADJ
dpc-4390	8	24	access	access	NOUN
dpc-4390	8	25	publishing	publishing	NOUN
dpc-4390	8	26	fees	fee	NOUN
dpc-4390	8	27	were	be	AUX
dpc-4390	8	28	supported	support	VERB
dpc-4390	8	29	by	by	ADP
dpc-4390	8	30	pierre	pierre	PROPN
dpc-4390	8	31	fabre	fabre	PROPN
dpc-4390	8	32	.	.	PUNCT
dpc-4390	9	1	competing	compete	VERB
dpc-4390	9	2	interests	interest	NOUN
dpc-4390	9	3	:	:	PUNCT
dpc-4390	9	4	pq	pq	PROPN
dpc-4390	9	5	has	have	AUX
dpc-4390	9	6	received	receive	VERB
dpc-4390	9	7	advisory	advisory	ADJ
dpc-4390	9	8	board	board	NOUN
dpc-4390	9	9	and	and	CCONJ
dpc-4390	9	10	speaker	speaker	NOUN
dpc-4390	9	11	fees	fee	NOUN
dpc-4390	9	12	from	from	ADP
dpc-4390	9	13	novartis	novartis	PROPN
dpc-4390	9	14	and	and	CCONJ
dpc-4390	9	15	pierre	pierre	PROPN
dpc-4390	9	16	-	-	PUNCT
dpc-4390	9	17	fabre	fabre	PROPN
dpc-4390	9	18	.	.	PUNCT
dpc-4390	10	1	ad	ad	NOUN
dpc-4390	10	2	,	,	PUNCT
dpc-4390	10	3	od	od	PROPN
dpc-4390	10	4	and	and	CCONJ
dpc-4390	10	5	fz	fz	PROPN
dpc-4390	10	6	are	be	AUX
dpc-4390	10	7	employees	employee	NOUN
dpc-4390	10	8	of	of	ADP
dpc-4390	10	9	pierre	pierre	PROPN
dpc-4390	10	10	fabre	fabre	PROPN
dpc-4390	10	11	.	.	PUNCT
dpc-4390	11	1	ga	ga	PROPN
dpc-4390	11	2	,	,	PUNCT
dpc-4390	11	3	ed	ed	PROPN
dpc-4390	11	4	,	,	PUNCT
dpc-4390	11	5	ms	ms	PROPN
dpc-4390	11	6	,	,	PUNCT
dpc-4390	11	7	sa	sa	PROPN
dpc-4390	11	8	,	,	PUNCT
dpc-4390	11	9	pf	pf	PROPN
dpc-4390	11	10	,	,	PUNCT
dpc-4390	11	11	em	em	PRON
dpc-4390	11	12	,	,	PUNCT
dpc-4390	11	13	bmp	bmp	PROPN
dpc-4390	11	14	have	have	VERB
dpc-4390	11	15	no	no	DET
dpc-4390	11	16	conflicts	conflict	NOUN
dpc-4390	11	17	of	of	ADP
dpc-4390	11	18	interest	interest	NOUN
dpc-4390	11	19	to	to	PART
dpc-4390	11	20	declare	declare	VERB
dpc-4390	11	21	.	.	PUNCT
dpc-4390	12	1	gg	gg	PROPN
dpc-4390	12	2	has	have	AUX
dpc-4390	12	3	received	receive	VERB
dpc-4390	12	4	personal	personal	ADJ
dpc-4390	12	5	fees	fee	NOUN
dpc-4390	12	6	from	from	ADP
dpc-4390	12	7	abbvie	abbvie	PROPN
dpc-4390	12	8	,	,	PUNCT
dpc-4390	12	9	almirall	almirall	PROPN
dpc-4390	12	10	,	,	PUNCT
dpc-4390	12	11	amgen	amgen	PROPN
dpc-4390	12	12	,	,	PUNCT
dpc-4390	12	13	boehringer	boehringer	PROPN
dpc-4390	12	14	-	-	PUNCT
dpc-4390	12	15	ingelheim	ingelheim	PROPN
dpc-4390	12	16	,	,	PUNCT
dpc-4390	12	17	bristol	bristol	PROPN
dpc-4390	12	18	-	-	PUNCT
dpc-4390	12	19	myers	myers	PROPN
dpc-4390	12	20	squibb	squibb	PROPN
dpc-4390	12	21	,	,	PUNCT
dpc-4390	12	22	eli	eli	PROPN
dpc-4390	12	23	-	-	PUNCT
dpc-4390	12	24	lilly	lilly	PROPN
dpc-4390	12	25	,	,	PUNCT
dpc-4390	12	26	leo	leo	PROPN
dpc-4390	12	27	pharma	pharma	PROPN
dpc-4390	12	28	,	,	PUNCT
dpc-4390	12	29	merck	merck	PROPN
dpc-4390	12	30	serono	serono	PROPN
dpc-4390	12	31	,	,	PUNCT
dpc-4390	12	32	novartis	novartis	NOUN
dpc-4390	12	33	,	,	PUNCT
dpc-4390	12	34	pfizer	pfizer	NOUN
dpc-4390	12	35	,	,	PUNCT
dpc-4390	12	36	pierre	pierre	PROPN
dpc-4390	12	37	fabre	fabre	PROPN
dpc-4390	12	38	,	,	PUNCT
dpc-4390	12	39	samsung	samsung	PROPN
dpc-4390	12	40	bioepis	bioepis	PROPN
dpc-4390	12	41	and	and	CCONJ
dpc-4390	12	42	sanofi	sanofi	PROPN
dpc-4390	12	43	.	.	PUNCT
dpc-4390	13	1	authorship	authorship	NOUN
dpc-4390	13	2	:	:	PUNCT
dpc-4390	13	3	all	all	DET
dpc-4390	13	4	authors	author	NOUN
dpc-4390	13	5	have	have	AUX
dpc-4390	13	6	contributed	contribute	VERB
dpc-4390	13	7	significantly	significantly	ADV
dpc-4390	13	8	to	to	ADP
dpc-4390	13	9	this	this	DET
dpc-4390	13	10	publication	publication	NOUN
dpc-4390	13	11	.	.	PUNCT
dpc-4390	14	1	corresponding	correspond	VERB
dpc-4390	14	2	author	author	NOUN
dpc-4390	14	3	:	:	PUNCT
dpc-4390	14	4	fabienne	fabienne	PROPN
dpc-4390	14	5	zumaglini	zumaglini	PROPN
dpc-4390	14	6	,	,	PUNCT
dpc-4390	14	7	pierre	pierre	PROPN
dpc-4390	14	8	fabre	fabre	PROPN
dpc-4390	14	9	dermatologie	dermatologie	PROPN
dpc-4390	14	10	,	,	PUNCT
dpc-4390	14	11	les	le	NOUN
dpc-4390	14	12	cauquillous	cauquillous	ADJ
dpc-4390	14	13	,	,	PUNCT
dpc-4390	14	14	81500	81500	NUM
dpc-4390	14	15	lavaur	lavaur	NOUN
dpc-4390	14	16	,	,	PUNCT
dpc-4390	14	17	france	france	PROPN
dpc-4390	14	18	.	.	PUNCT
dpc-4390	15	1	phone	phone	NOUN
dpc-4390	15	2	:	:	PUNCT
dpc-4390	16	1	+33	+33	NOUN
dpc-4390	16	2	642	642	NUM
dpc-4390	16	3	44	44	NUM
dpc-4390	16	4	41	41	NUM
dpc-4390	16	5	15	15	NUM
dpc-4390	16	6	e	e	NOUN
dpc-4390	16	7	-	-	NOUN
dpc-4390	16	8	mail	mail	NOUN
dpc-4390	16	9	:	:	PUNCT
dpc-4390	16	10	fabienne.zumaglini@pierre-fabre.com	fabienne.zumaglini@pierre-fabre.com	X
dpc-4390	16	11	introduction	introduction	NOUN
dpc-4390	16	12	dermatological	dermatological	ADJ
dpc-4390	16	13	adverse	adverse	ADJ
dpc-4390	16	14	events	event	NOUN
dpc-4390	16	15	are	be	AUX
dpc-4390	16	16	commonly	commonly	ADV
dpc-4390	16	17	experienced	experience	VERB
dpc-4390	16	18	by	by	ADP
dpc-4390	16	19	patients	patient	NOUN
dpc-4390	16	20	during	during	ADP
dpc-4390	16	21	anticancer	anticancer	NOUN
dpc-4390	16	22	treatment	treatment	NOUN
dpc-4390	16	23	[	[	X
dpc-4390	16	24	1	1	NUM
dpc-4390	16	25	,	,	PUNCT
dpc-4390	16	26	2	2	NUM
dpc-4390	16	27	]	]	PUNCT
dpc-4390	16	28	.	.	PUNCT
dpc-4390	17	1	xerosis	xerosis	PROPN
dpc-4390	17	2	is	be	AUX
dpc-4390	17	3	frequently	frequently	ADV
dpc-4390	17	4	associated	associate	VERB
dpc-4390	17	5	with	with	ADP
dpc-4390	17	6	epidermal	epidermal	ADJ
dpc-4390	17	7	growth	growth	NOUN
dpc-4390	17	8	factor	factor	NOUN
dpc-4390	17	9	receptor	receptor	NOUN
dpc-4390	17	10	inhibitor	inhibitor	NOUN
dpc-4390	17	11	(	(	PUNCT
dpc-4390	17	12	egfri	egfri	PROPN
dpc-4390	17	13	)	)	PUNCT
dpc-4390	17	14	or	or	CCONJ
dpc-4390	17	15	mitogen	mitogen	NOUN
dpc-4390	17	16	-	-	PUNCT
dpc-4390	17	17	activated	activate	VERB
dpc-4390	17	18	protein	protein	NOUN
dpc-4390	17	19	kinase	kinase	NOUN
dpc-4390	17	20	inhibitor	inhibitor	NOUN
dpc-4390	17	21	(	(	PUNCT
dpc-4390	17	22	meki	meki	PROPN
dpc-4390	17	23	)	)	PUNCT
dpc-4390	17	24	treatment	treatment	NOUN
dpc-4390	17	25	[	[	X
dpc-4390	17	26	3	3	NUM
dpc-4390	17	27	]	]	PUNCT
dpc-4390	17	28	.	.	PUNCT
dpc-4390	18	1	while	while	SCONJ
dpc-4390	18	2	xerosis	xerosis	NOUN
dpc-4390	18	3	is	be	AUX
dpc-4390	18	4	typically	typically	ADV
dpc-4390	18	5	mild	mild	ADJ
dpc-4390	18	6	-	-	PUNCT
dpc-4390	18	7	to	to	ADP
dpc-4390	18	8	-	-	PUNCT
dpc-4390	18	9	moderate	moderate	ADJ
dpc-4390	18	10	in	in	ADP
dpc-4390	18	11	intensity	intensity	NOUN
dpc-4390	18	12	,	,	PUNCT
dpc-4390	18	13	it	it	PRON
dpc-4390	18	14	can	can	AUX
dpc-4390	18	15	significantly	significantly	ADV
dpc-4390	18	16	impact	impact	VERB
dpc-4390	18	17	quality	quality	NOUN
dpc-4390	18	18	of	of	ADP
dpc-4390	18	19	life	life	NOUN
dpc-4390	18	20	[	[	X
dpc-4390	18	21	4	4	NUM
dpc-4390	18	22	]	]	PUNCT
dpc-4390	18	23	,	,	PUNCT
dpc-4390	18	24	especially	especially	ADV
dpc-4390	18	25	in	in	ADP
dpc-4390	18	26	patients	patient	NOUN
dpc-4390	18	27	receiving	receive	VERB
dpc-4390	18	28	long	long	ADJ
dpc-4390	18	29	-	-	PUNCT
dpc-4390	18	30	term	term	NOUN
dpc-4390	18	31	anticancer	anticancer	NOUN
dpc-4390	18	32	therapy	therapy	NOUN
dpc-4390	18	33	.	.	PUNCT
dpc-4390	19	1	2	2	NUM
dpc-4390	19	2	research	research	NOUN
dpc-4390	19	3	letter	letter	NOUN
dpc-4390	19	4	|	|	ADV
dpc-4390	19	5	dermatol	dermatol	ADJ
dpc-4390	19	6	pract	pract	NOUN
dpc-4390	19	7	concept	concept	NOUN
dpc-4390	19	8	.	.	PUNCT
dpc-4390	20	1	2024;14(4):e2024259	2024;14(4):e2024259	NUM
dpc-4390	20	2	case	case	NOUN
dpc-4390	20	3	presentation	presentation	NOUN
dpc-4390	20	4	we	we	PRON
dpc-4390	20	5	conducted	conduct	VERB
dpc-4390	20	6	a	a	DET
dpc-4390	20	7	non	non	ADJ
dpc-4390	20	8	-	-	ADJ
dpc-4390	20	9	interventional	interventional	ADJ
dpc-4390	20	10	prospective	prospective	ADJ
dpc-4390	20	11	pilot	pilot	NOUN
dpc-4390	20	12	study	study	NOUN
dpc-4390	20	13	at	at	ADP
dpc-4390	20	14	three	three	NUM
dpc-4390	20	15	oncology	oncology	NOUN
dpc-4390	20	16	centers	center	NOUN
dpc-4390	20	17	in	in	ADP
dpc-4390	20	18	italy	italy	PROPN
dpc-4390	20	19	to	to	PART
dpc-4390	20	20	identify	identify	VERB
dpc-4390	20	21	the	the	DET
dpc-4390	20	22	proportion	proportion	NOUN
dpc-4390	20	23	of	of	ADP
dpc-4390	20	24	patients	patient	NOUN
dpc-4390	20	25	with	with	ADP
dpc-4390	20	26	emerging	emerge	VERB
dpc-4390	20	27	or	or	CCONJ
dpc-4390	20	28	worsening	worsen	VERB
dpc-4390	20	29	xerosis	xerosis	NOUN
dpc-4390	20	30	among	among	ADP
dpc-4390	20	31	those	those	PRON
dpc-4390	20	32	receiving	receive	VERB
dpc-4390	20	33	targeted	target	VERB
dpc-4390	20	34	anticancer	anticancer	NOUN
dpc-4390	20	35	therapies	therapy	NOUN
dpc-4390	20	36	associated	associate	VERB
dpc-4390	20	37	with	with	ADP
dpc-4390	20	38	the	the	DET
dpc-4390	20	39	highest	high	ADJ
dpc-4390	20	40	risk	risk	NOUN
dpc-4390	20	41	of	of	ADP
dpc-4390	20	42	xerosis	xerosis	NOUN
dpc-4390	20	43	:	:	PUNCT
dpc-4390	20	44	egfris	egfris	ADJ
dpc-4390	20	45	and	and	CCONJ
dpc-4390	20	46	mekis	meki	NOUN
dpc-4390	20	47	.	.	PUNCT
dpc-4390	21	1	eligible	eligible	ADJ
dpc-4390	21	2	patients	patient	NOUN
dpc-4390	21	3	were	be	AUX
dpc-4390	21	4	≥18	≥18	NUM
dpc-4390	21	5	years	year	NOUN
dpc-4390	21	6	old	old	ADJ
dpc-4390	21	7	with	with	ADP
dpc-4390	21	8	cancer	cancer	NOUN
dpc-4390	21	9	initiating	initiate	VERB
dpc-4390	21	10	treatment	treatment	NOUN
dpc-4390	21	11	with	with	ADP
dpc-4390	21	12	an	an	DET
dpc-4390	21	13	egfri	egfri	NOUN
dpc-4390	21	14	or	or	CCONJ
dpc-4390	21	15	meki	meki	NOUN
dpc-4390	21	16	.	.	PUNCT
dpc-4390	22	1	patients	patient	NOUN
dpc-4390	22	2	were	be	AUX
dpc-4390	22	3	assessed	assess	VERB
dpc-4390	22	4	at	at	ADP
dpc-4390	22	5	three	three	NUM
dpc-4390	22	6	study	study	NOUN
dpc-4390	22	7	visits	visit	NOUN
dpc-4390	22	8	(	(	PUNCT
dpc-4390	22	9	visit	visit	VERB
dpc-4390	22	10	1	1	NUM
dpc-4390	22	11	was	be	AUX
dpc-4390	22	12	considered	consider	VERB
dpc-4390	22	13	baseline	baseline	ADJ
dpc-4390	22	14	)	)	PUNCT
dpc-4390	22	15	.	.	PUNCT
dpc-4390	23	1	study	study	NOUN
dpc-4390	23	2	assessments	assessment	NOUN
dpc-4390	23	3	included	include	VERB
dpc-4390	23	4	xerosis	xerosis	NOUN
dpc-4390	23	5	severity	severity	NOUN
dpc-4390	23	6	(	(	PUNCT
dpc-4390	23	7	using	use	VERB
dpc-4390	23	8	overall	overall	ADJ
dpc-4390	23	9	dry	dry	ADJ
dpc-4390	23	10	skin	skin	NOUN
dpc-4390	23	11	[	[	X
dpc-4390	23	12	ods	ods	X
dpc-4390	23	13	]	]	PUNCT
dpc-4390	23	14	scores	score	NOUN
dpc-4390	23	15	and	and	CCONJ
dpc-4390	23	16	common	common	ADJ
dpc-4390	23	17	terminology	terminology	NOUN
dpc-4390	23	18	criteria	criterion	NOUN
dpc-4390	23	19	for	for	ADP
dpc-4390	23	20	adverse	adverse	ADJ
dpc-4390	23	21	events	event	NOUN
dpc-4390	23	22	[	[	X
dpc-4390	23	23	ctcae	ctcae	NOUN
dpc-4390	23	24	]	]	X
dpc-4390	23	25	classifications	classification	NOUN
dpc-4390	23	26	)	)	PUNCT
dpc-4390	23	27	,	,	PUNCT
dpc-4390	23	28	skin	skin	NOUN
dpc-4390	23	29	dryness	dryness	NOUN
dpc-4390	23	30	(	(	PUNCT
dpc-4390	23	31	using	use	VERB
dpc-4390	23	32	hydration	hydration	NOUN
dpc-4390	23	33	index	index	NOUN
dpc-4390	23	34	[	[	X
dpc-4390	23	35	hi	hi	INTJ
dpc-4390	23	36	]	]	X
dpc-4390	23	37	scores	score	NOUN
dpc-4390	23	38	)	)	PUNCT
dpc-4390	23	39	,	,	PUNCT
dpc-4390	23	40	and	and	CCONJ
dpc-4390	23	41	treatments	treatment	NOUN
dpc-4390	23	42	.	.	PUNCT
dpc-4390	24	1	between	between	ADP
dpc-4390	24	2	2019	2019	NUM
dpc-4390	24	3	and	and	CCONJ
dpc-4390	24	4	2022	2022	NUM
dpc-4390	24	5	,	,	PUNCT
dpc-4390	24	6	22	22	NUM
dpc-4390	24	7	patients	patient	NOUN
dpc-4390	24	8	(	(	PUNCT
dpc-4390	24	9	mean	mean	VERB
dpc-4390	24	10	age	age	NOUN
dpc-4390	24	11	57.3	57.3	NUM
dpc-4390	24	12	years	year	NOUN
dpc-4390	24	13	)	)	PUNCT
dpc-4390	24	14	completed	complete	VERB
dpc-4390	24	15	all	all	DET
dpc-4390	24	16	three	three	NUM
dpc-4390	24	17	study	study	NOUN
dpc-4390	24	18	visits	visit	NOUN
dpc-4390	24	19	.	.	PUNCT
dpc-4390	25	1	the	the	DET
dpc-4390	25	2	majority	majority	NOUN
dpc-4390	25	3	(	(	PUNCT
dpc-4390	25	4	90.9	90.9	NUM
dpc-4390	25	5	%	%	NOUN
dpc-4390	25	6	)	)	PUNCT
dpc-4390	25	7	received	receive	VERB
dpc-4390	25	8	a	a	DET
dpc-4390	25	9	meki	meki	NOUN
dpc-4390	25	10	(	(	PUNCT
dpc-4390	25	11	trametinib	trametinib	NOUN
dpc-4390	25	12	:	:	PUNCT
dpc-4390	25	13	n=18	n=18	ADJ
dpc-4390	25	14	,	,	PUNCT
dpc-4390	25	15	binimetinib	binimetinib	NOUN
dpc-4390	25	16	:	:	PUNCT
dpc-4390	25	17	n=2	n=2	ADV
dpc-4390	25	18	)	)	PUNCT
dpc-4390	25	19	and	and	CCONJ
dpc-4390	25	20	two	two	NUM
dpc-4390	25	21	(	(	PUNCT
dpc-4390	25	22	9.1	9.1	NUM
dpc-4390	25	23	%	%	NOUN
dpc-4390	25	24	)	)	PUNCT
dpc-4390	25	25	patients	patient	NOUN
dpc-4390	25	26	received	receive	VERB
dpc-4390	25	27	an	an	DET
dpc-4390	25	28	egfri	egfri	ADJ
dpc-4390	25	29	(	(	PUNCT
dpc-4390	25	30	osimertinib	osimertinib	NOUN
dpc-4390	25	31	)	)	PUNCT
dpc-4390	25	32	.	.	PUNCT
dpc-4390	26	1	mekis	meki	NOUN
dpc-4390	26	2	were	be	AUX
dpc-4390	26	3	administered	administer	VERB
dpc-4390	26	4	with	with	ADP
dpc-4390	26	5	a	a	DET
dpc-4390	26	6	braf	braf	NOUN
dpc-4390	26	7	inhibitor	inhibitor	NOUN
dpc-4390	26	8	in	in	ADP
dpc-4390	26	9	all	all	PRON
dpc-4390	26	10	but	but	SCONJ
dpc-4390	26	11	one	one	NUM
dpc-4390	26	12	patient	patient	NOUN
dpc-4390	26	13	.	.	PUNCT
dpc-4390	27	1	of	of	ADP
dpc-4390	27	2	these	these	DET
dpc-4390	27	3	22	22	NUM
dpc-4390	27	4	patients	patient	NOUN
dpc-4390	27	5	,	,	PUNCT
dpc-4390	27	6	five	five	NUM
dpc-4390	27	7	(	(	PUNCT
dpc-4390	27	8	22.7	22.7	NUM
dpc-4390	27	9	%	%	NOUN
dpc-4390	27	10	)	)	PUNCT
dpc-4390	27	11	either	either	CCONJ
dpc-4390	27	12	developed	develop	VERB
dpc-4390	27	13	xerosis	xerosis	NOUN
dpc-4390	27	14	(	(	PUNCT
dpc-4390	27	15	n=3	n=3	NOUN
dpc-4390	27	16	;	;	PUNCT
dpc-4390	27	17	13.6	13.6	NUM
dpc-4390	27	18	%	%	NOUN
dpc-4390	27	19	,	,	PUNCT
dpc-4390	27	20	95	95	NUM
dpc-4390	27	21	%	%	NOUN
dpc-4390	27	22	ci	ci	NOUN
dpc-4390	27	23	:	:	PUNCT
dpc-4390	27	24	2.9–34.9	2.9–34.9	NUM
dpc-4390	27	25	)	)	PUNCT
dpc-4390	27	26	or	or	CCONJ
dpc-4390	27	27	had	have	VERB
dpc-4390	27	28	a	a	DET
dpc-4390	27	29	worsening	worsening	NOUN
dpc-4390	27	30	of	of	ADP
dpc-4390	27	31	their	their	PRON
dpc-4390	27	32	preexisting	preexist	VERB
dpc-4390	27	33	xerosis	xerosis	NOUN
dpc-4390	27	34	(	(	PUNCT
dpc-4390	27	35	n=2	n=2	ADV
dpc-4390	27	36	;	;	PUNCT
dpc-4390	27	37	9.1	9.1	NUM
dpc-4390	27	38	%	%	NOUN
dpc-4390	27	39	,	,	PUNCT
dpc-4390	27	40	95	95	NUM
dpc-4390	27	41	%	%	NOUN
dpc-4390	27	42	ci	ci	NOUN
dpc-4390	27	43	:	:	PUNCT
dpc-4390	27	44	1.1–29.2	1.1–29.2	NUM
dpc-4390	27	45	)	)	PUNCT
dpc-4390	27	46	during	during	ADP
dpc-4390	27	47	treatment	treatment	NOUN
dpc-4390	27	48	(	(	PUNCT
dpc-4390	27	49	figure	figure	NOUN
dpc-4390	27	50	1	1	NUM
dpc-4390	27	51	)	)	PUNCT
dpc-4390	27	52	.	.	PUNCT
dpc-4390	28	1	xerosis	xerosis	PROPN
dpc-4390	28	2	severity	severity	NOUN
dpc-4390	28	3	figure	figure	NOUN
dpc-4390	28	4	1	1	NUM
dpc-4390	28	5	.	.	PUNCT
dpc-4390	28	6	number	number	NOUN
dpc-4390	28	7	of	of	ADP
dpc-4390	28	8	patients	patient	NOUN
dpc-4390	28	9	who	who	PRON
dpc-4390	28	10	attended	attend	VERB
dpc-4390	28	11	all	all	DET
dpc-4390	28	12	three	three	NUM
dpc-4390	28	13	study	study	NOUN
dpc-4390	28	14	visits	visit	NOUN
dpc-4390	28	15	with	with	ADP
dpc-4390	28	16	emerging	emerge	VERB
dpc-4390	28	17	or	or	CCONJ
dpc-4390	28	18	worsening	worsen	VERB
dpc-4390	28	19	xerosis	xerosis	NOUN
dpc-4390	28	20	while	while	SCONJ
dpc-4390	28	21	receiving	receive	VERB
dpc-4390	28	22	epidermal	epidermal	ADJ
dpc-4390	28	23	growth	growth	NOUN
dpc-4390	28	24	factor	factor	NOUN
dpc-4390	28	25	receptor	receptor	NOUN
dpc-4390	28	26	or	or	CCONJ
dpc-4390	28	27	mitogen	mitogen	NOUN
dpc-4390	28	28	-	-	PUNCT
dpc-4390	28	29	activated	activate	VERB
dpc-4390	28	30	protein	protein	NOUN
dpc-4390	28	31	kinase	kinase	NOUN
dpc-4390	28	32	inhibitors	inhibitor	NOUN
dpc-4390	28	33	(	(	PUNCT
dpc-4390	28	34	n=22	n=22	PROPN
dpc-4390	28	35	)	)	PUNCT
dpc-4390	28	36	.	.	PUNCT
dpc-4390	29	1	table	table	NOUN
dpc-4390	29	2	1	1	NUM
dpc-4390	29	3	.	.	PUNCT
dpc-4390	30	1	outcomes	outcome	NOUN
dpc-4390	30	2	in	in	ADP
dpc-4390	30	3	the	the	DET
dpc-4390	30	4	patients	patient	NOUN
dpc-4390	30	5	who	who	PRON
dpc-4390	30	6	attended	attend	VERB
dpc-4390	30	7	all	all	DET
dpc-4390	30	8	3	3	NUM
dpc-4390	30	9	study	study	NOUN
dpc-4390	30	10	visits	visit	NOUN
dpc-4390	30	11	(	(	PUNCT
dpc-4390	30	12	n=22	n=22	PROPN
dpc-4390	30	13	)	)	PUNCT
dpc-4390	30	14	.	.	PUNCT
dpc-4390	31	1	visit	visit	VERB
dpc-4390	31	2	1	1	NUM
dpc-4390	31	3	(	(	PUNCT
dpc-4390	31	4	bl	bl	NOUN
dpc-4390	31	5	)	)	PUNCT
dpc-4390	31	6	visit	visit	VERB
dpc-4390	31	7	2	2	NUM
dpc-4390	31	8	visit	visit	NOUN
dpc-4390	31	9	3	3	NUM
dpc-4390	31	10	xerosis	xerosis	NOUN
dpc-4390	31	11	,	,	PUNCT
dpc-4390	31	12	n	n	CCONJ
dpc-4390	31	13	(	(	PUNCT
dpc-4390	31	14	%	%	INTJ
dpc-4390	31	15	)	)	PUNCT
dpc-4390	31	16	6	6	NUM
dpc-4390	31	17	(	(	PUNCT
dpc-4390	31	18	27.3	27.3	NUM
dpc-4390	31	19	)	)	PUNCT
dpc-4390	31	20	5a	5a	NUM
dpc-4390	31	21	(	(	PUNCT
dpc-4390	31	22	22.7	22.7	NUM
dpc-4390	31	23	)	)	PUNCT
dpc-4390	31	24	8b	8b	PROPN
dpc-4390	31	25	(	(	PUNCT
dpc-4390	31	26	36.4	36.4	NUM
dpc-4390	31	27	)	)	PUNCT
dpc-4390	31	28	xerosis	xerosis	NOUN
dpc-4390	31	29	location	location	NOUN
dpc-4390	31	30	,	,	PUNCT
dpc-4390	31	31	n	n	CCONJ
dpc-4390	31	32	(	(	PUNCT
dpc-4390	31	33	%	%	INTJ
dpc-4390	31	34	)	)	PUNCT
dpc-4390	31	35	lower	low	ADJ
dpc-4390	31	36	limbs	limb	NOUN
dpc-4390	31	37	4	4	NUM
dpc-4390	31	38	(	(	PUNCT
dpc-4390	31	39	18.2	18.2	NUM
dpc-4390	31	40	)	)	PUNCT
dpc-4390	31	41	4	4	NUM
dpc-4390	31	42	(	(	PUNCT
dpc-4390	31	43	18.2	18.2	NUM
dpc-4390	31	44	)	)	PUNCT
dpc-4390	31	45	7	7	NUM
dpc-4390	31	46	(	(	PUNCT
dpc-4390	31	47	31.8	31.8	NUM
dpc-4390	31	48	)	)	PUNCT
dpc-4390	31	49	upper	upper	ADJ
dpc-4390	31	50	limbs	limb	NOUN
dpc-4390	31	51	3	3	NUM
dpc-4390	31	52	(	(	PUNCT
dpc-4390	31	53	13.6	13.6	NUM
dpc-4390	31	54	)	)	PUNCT
dpc-4390	31	55	4	4	NUM
dpc-4390	31	56	(	(	PUNCT
dpc-4390	31	57	18.2	18.2	NUM
dpc-4390	31	58	)	)	PUNCT
dpc-4390	31	59	6	6	NUM
dpc-4390	31	60	(	(	PUNCT
dpc-4390	31	61	27.3	27.3	NUM
dpc-4390	31	62	)	)	PUNCT
dpc-4390	31	63	hands	hand	NOUN
dpc-4390	31	64	2	2	NUM
dpc-4390	31	65	(	(	PUNCT
dpc-4390	31	66	9.1	9.1	NUM
dpc-4390	31	67	)	)	SYM
dpc-4390	31	68	2	2	NUM
dpc-4390	31	69	(	(	PUNCT
dpc-4390	31	70	9.1	9.1	NUM
dpc-4390	31	71	)	)	PUNCT
dpc-4390	31	72	3	3	NUM
dpc-4390	31	73	(	(	PUNCT
dpc-4390	31	74	13.6	13.6	NUM
dpc-4390	31	75	)	)	PUNCT
dpc-4390	31	76	emollients	emollient	NOUN
dpc-4390	31	77	,	,	PUNCT
dpc-4390	31	78	n	n	CCONJ
dpc-4390	31	79	(	(	PUNCT
dpc-4390	31	80	%	%	INTJ
dpc-4390	31	81	)	)	PUNCT
dpc-4390	31	82	7	7	NUM
dpc-4390	31	83	(	(	PUNCT
dpc-4390	31	84	31.8	31.8	NUM
dpc-4390	31	85	)	)	PUNCT
dpc-4390	31	86	7	7	NUM
dpc-4390	31	87	(	(	PUNCT
dpc-4390	31	88	31.8	31.8	NUM
dpc-4390	31	89	)	)	PUNCT
dpc-4390	31	90	8	8	NUM
dpc-4390	31	91	(	(	PUNCT
dpc-4390	31	92	36.4	36.4	NUM
dpc-4390	31	93	)	)	PUNCT
dpc-4390	31	94	emollients	emollient	NOUN
dpc-4390	31	95	and	and	CCONJ
dpc-4390	31	96	topical	topical	ADJ
dpc-4390	31	97	barrier	barrier	NOUN
dpc-4390	31	98	products	product	NOUN
dpc-4390	31	99	5	5	NUM
dpc-4390	31	100	(	(	PUNCT
dpc-4390	31	101	22.7	22.7	NUM
dpc-4390	31	102	)	)	PUNCT
dpc-4390	31	103	6	6	NUM
dpc-4390	31	104	(	(	PUNCT
dpc-4390	31	105	27.3	27.3	NUM
dpc-4390	31	106	)	)	PUNCT
dpc-4390	31	107	8	8	NUM
dpc-4390	31	108	(	(	PUNCT
dpc-4390	31	109	36.4	36.4	NUM
dpc-4390	31	110	)	)	PUNCT
dpc-4390	31	111	ods	od	NOUN
dpc-4390	31	112	score	score	NOUN
dpc-4390	31	113	,	,	PUNCT
dpc-4390	31	114	mean	mean	VERB
dpc-4390	31	115	±	±	NUM
dpc-4390	31	116	sd	sd	ADP
dpc-4390	31	117	0.32	0.32	NUM
dpc-4390	31	118	±	±	NUM
dpc-4390	31	119	0.6	0.6	NUM
dpc-4390	31	120	0.32	0.32	NUM
dpc-4390	31	121	±	±	NUM
dpc-4390	31	122	0.6	0.6	NUM
dpc-4390	31	123	0.64	0.64	NUM
dpc-4390	31	124	±	±	NUM
dpc-4390	31	125	1.0	1.0	NUM
dpc-4390	31	126	ods	od	NOUN
dpc-4390	31	127	score	score	NOUN
dpc-4390	31	128	,	,	PUNCT
dpc-4390	31	129	n	n	PROPN
dpc-4390	31	130	(	(	PUNCT
dpc-4390	31	131	%	%	INTJ
dpc-4390	31	132	)	)	PUNCT
dpc-4390	31	133	0	0	NUM
dpc-4390	31	134	16	16	NUM
dpc-4390	31	135	(	(	PUNCT
dpc-4390	31	136	72.7	72.7	NUM
dpc-4390	31	137	)	)	PUNCT
dpc-4390	31	138	17	17	NUM
dpc-4390	31	139	(	(	PUNCT
dpc-4390	31	140	77.3	77.3	NUM
dpc-4390	31	141	)	)	PUNCT
dpc-4390	31	142	14	14	NUM
dpc-4390	31	143	(	(	PUNCT
dpc-4390	31	144	63.6	63.6	NUM
dpc-4390	31	145	)	)	PUNCT
dpc-4390	31	146	1	1	NUM
dpc-4390	31	147	5	5	NUM
dpc-4390	31	148	(	(	PUNCT
dpc-4390	31	149	22.7	22.7	NUM
dpc-4390	31	150	)	)	SYM
dpc-4390	31	151	3	3	NUM
dpc-4390	31	152	(	(	PUNCT
dpc-4390	31	153	13.6	13.6	NUM
dpc-4390	31	154	)	)	PUNCT
dpc-4390	31	155	3	3	NUM
dpc-4390	31	156	(	(	PUNCT
dpc-4390	31	157	13.6	13.6	NUM
dpc-4390	31	158	)	)	PUNCT
dpc-4390	31	159	2	2	NUM
dpc-4390	31	160	1	1	NUM
dpc-4390	31	161	(	(	PUNCT
dpc-4390	31	162	4.5	4.5	NUM
dpc-4390	31	163	)	)	PUNCT
dpc-4390	31	164	2	2	NUM
dpc-4390	31	165	(	(	PUNCT
dpc-4390	31	166	9.1	9.1	NUM
dpc-4390	31	167	)	)	PUNCT
dpc-4390	31	168	4	4	NUM
dpc-4390	31	169	(	(	PUNCT
dpc-4390	31	170	18.2	18.2	NUM
dpc-4390	31	171	)	)	PUNCT
dpc-4390	31	172	3	3	NUM
dpc-4390	31	173	0	0	NUM
dpc-4390	31	174	0	0	NUM
dpc-4390	31	175	1	1	NUM
dpc-4390	31	176	(	(	PUNCT
dpc-4390	31	177	4.5	4.5	NUM
dpc-4390	31	178	)	)	PUNCT
dpc-4390	31	179	xerosis	xerosis	NOUN
dpc-4390	31	180	severity	severity	NOUN
dpc-4390	31	181	,	,	PUNCT
dpc-4390	31	182	ctcae	ctcae	NOUN
dpc-4390	31	183	classification	classification	NOUN
dpc-4390	31	184	,	,	PUNCT
dpc-4390	31	185	n	n	CCONJ
dpc-4390	31	186	(	(	PUNCT
dpc-4390	31	187	%	%	INTJ
dpc-4390	31	188	)	)	PUNCT
dpc-4390	31	189	grade	grade	NOUN
dpc-4390	31	190	1	1	NUM
dpc-4390	31	191	6	6	NUM
dpc-4390	31	192	(	(	PUNCT
dpc-4390	31	193	27.3	27.3	NUM
dpc-4390	31	194	)	)	PUNCT
dpc-4390	31	195	4	4	NUM
dpc-4390	31	196	(	(	PUNCT
dpc-4390	31	197	18.2	18.2	NUM
dpc-4390	31	198	)	)	PUNCT
dpc-4390	31	199	5	5	NUM
dpc-4390	31	200	(	(	PUNCT
dpc-4390	31	201	22.7	22.7	NUM
dpc-4390	31	202	)	)	PUNCT
dpc-4390	31	203	grade	grade	NOUN
dpc-4390	31	204	2	2	NUM
dpc-4390	31	205	0	0	NUM
dpc-4390	31	206	1	1	NUM
dpc-4390	31	207	(	(	PUNCT
dpc-4390	31	208	4.5	4.5	NUM
dpc-4390	31	209	)	)	PUNCT
dpc-4390	31	210	3	3	NUM
dpc-4390	31	211	(	(	PUNCT
dpc-4390	31	212	13.6	13.6	NUM
dpc-4390	31	213	)	)	PUNCT
dpc-4390	31	214	hi	hi	NOUN
dpc-4390	31	215	score	score	NOUN
dpc-4390	31	216	,	,	PUNCT
dpc-4390	31	217	mean	mean	VERB
dpc-4390	31	218	±	±	NUM
dpc-4390	31	219	sd	sd	ADP
dpc-4390	31	220	38.59	38.59	NUM
dpc-4390	31	221	±	±	NUM
dpc-4390	31	222	13.36	13.36	NUM
dpc-4390	31	223	33.48	33.48	NUM
dpc-4390	31	224	±	±	NUM
dpc-4390	31	225	11.17	11.17	NUM
dpc-4390	31	226	31.66	31.66	NUM
dpc-4390	31	227	±	±	NUM
dpc-4390	31	228	14.10c	14.10c	NUM
dpc-4390	31	229	hi	hi	NOUN
dpc-4390	31	230	score	score	NOUN
dpc-4390	31	231	,	,	PUNCT
dpc-4390	31	232	n	n	CCONJ
dpc-4390	31	233	(	(	PUNCT
dpc-4390	31	234	%	%	INTJ
dpc-4390	31	235	)	)	PUNCT
dpc-4390	32	1	<	<	X
dpc-4390	32	2	30	30	NUM
dpc-4390	32	3	(	(	PUNCT
dpc-4390	32	4	very	very	ADV
dpc-4390	32	5	dry	dry	ADJ
dpc-4390	32	6	)	)	PUNCT
dpc-4390	32	7	6	6	NUM
dpc-4390	32	8	(	(	PUNCT
dpc-4390	32	9	27.3	27.3	NUM
dpc-4390	32	10	)	)	PUNCT
dpc-4390	32	11	8	8	NUM
dpc-4390	32	12	(	(	PUNCT
dpc-4390	32	13	36.4	36.4	NUM
dpc-4390	32	14	)	)	PUNCT
dpc-4390	32	15	10	10	NUM
dpc-4390	32	16	(	(	PUNCT
dpc-4390	32	17	47.6)c	47.6)c	PROPN
dpc-4390	32	18	30–45	30–45	NUM
dpc-4390	32	19	(	(	PUNCT
dpc-4390	32	20	dry	dry	PROPN
dpc-4390	32	21	)	)	PUNCT
dpc-4390	32	22	8	8	NUM
dpc-4390	32	23	(	(	PUNCT
dpc-4390	32	24	36.4	36.4	NUM
dpc-4390	32	25	)	)	PUNCT
dpc-4390	32	26	11	11	NUM
dpc-4390	32	27	(	(	PUNCT
dpc-4390	32	28	50.0	50.0	NUM
dpc-4390	32	29	)	)	PUNCT
dpc-4390	32	30	6	6	NUM
dpc-4390	32	31	(	(	PUNCT
dpc-4390	32	32	28.6)c	28.6)c	NUM
dpc-4390	32	33	>	>	PUNCT
dpc-4390	32	34	45	45	NUM
dpc-4390	32	35	(	(	PUNCT
dpc-4390	32	36	sufficiently	sufficiently	ADV
dpc-4390	32	37	hydrated	hydrated	ADJ
dpc-4390	32	38	)	)	PUNCT
dpc-4390	32	39	8	8	NUM
dpc-4390	32	40	(	(	PUNCT
dpc-4390	32	41	36.4	36.4	NUM
dpc-4390	32	42	)	)	PUNCT
dpc-4390	32	43	3	3	NUM
dpc-4390	32	44	(	(	PUNCT
dpc-4390	32	45	13.6	13.6	NUM
dpc-4390	32	46	)	)	SYM
dpc-4390	32	47	5	5	NUM
dpc-4390	32	48	(	(	PUNCT
dpc-4390	32	49	23.8)c	23.8)c	NUM
dpc-4390	32	50	axerosis	axerosis	NOUN
dpc-4390	32	51	resolved	resolve	VERB
dpc-4390	32	52	in	in	ADP
dpc-4390	32	53	one	one	NUM
dpc-4390	32	54	patient	patient	NOUN
dpc-4390	32	55	between	between	ADP
dpc-4390	32	56	baseline	baseline	NOUN
dpc-4390	32	57	and	and	CCONJ
dpc-4390	32	58	visit	visit	VERB
dpc-4390	32	59	2	2	NUM
dpc-4390	32	60	,	,	PUNCT
dpc-4390	32	61	then	then	ADV
dpc-4390	32	62	reappeared	reappear	VERB
dpc-4390	32	63	at	at	ADP
dpc-4390	32	64	visit	visit	NOUN
dpc-4390	32	65	3	3	NUM
dpc-4390	32	66	;	;	PUNCT
dpc-4390	32	67	bxerosis	bxerosis	NOUN
dpc-4390	32	68	resolved	resolve	VERB
dpc-4390	32	69	in	in	ADP
dpc-4390	32	70	one	one	NUM
dpc-4390	32	71	patient	patient	NOUN
dpc-4390	32	72	after	after	ADP
dpc-4390	32	73	the	the	DET
dpc-4390	32	74	baseline	baseline	PROPN
dpc-4390	32	75	visit	visit	NOUN
dpc-4390	32	76	;	;	PUNCT
dpc-4390	33	1	cn=21	cn=21	PROPN
dpc-4390	33	2	.	.	PUNCT
dpc-4390	33	3	abbreviations	abbreviation	NOUN
dpc-4390	33	4	:	:	PUNCT
dpc-4390	33	5	bl	bl	ADP
dpc-4390	33	6	:	:	PUNCT
dpc-4390	33	7	baseline	baseline	PROPN
dpc-4390	33	8	;	;	PUNCT
dpc-4390	33	9	ctcae	ctcae	NOUN
dpc-4390	33	10	:	:	PUNCT
dpc-4390	33	11	common	common	ADJ
dpc-4390	33	12	terminology	terminology	NOUN
dpc-4390	33	13	criteria	criterion	NOUN
dpc-4390	33	14	for	for	ADP
dpc-4390	33	15	adverse	adverse	ADJ
dpc-4390	33	16	events	event	NOUN
dpc-4390	33	17	;	;	PUNCT
dpc-4390	33	18	hi	hi	ADJ
dpc-4390	33	19	:	:	PUNCT
dpc-4390	33	20	hydration	hydration	NOUN
dpc-4390	33	21	index	index	NOUN
dpc-4390	33	22	;	;	PUNCT
dpc-4390	33	23	ods	od	NOUN
dpc-4390	33	24	:	:	PUNCT
dpc-4390	33	25	overall	overall	ADJ
dpc-4390	33	26	dry	dry	ADJ
dpc-4390	33	27	skin	skin	NOUN
dpc-4390	33	28	;	;	PUNCT
dpc-4390	33	29	sd	sd	NUM
dpc-4390	33	30	:	:	PUNCT
dpc-4390	33	31	standard	standard	ADJ
dpc-4390	33	32	deviation	deviation	NOUN
dpc-4390	33	33	.	.	PUNCT
dpc-4390	34	1	(	(	PUNCT
dpc-4390	34	2	ctcae	ctcae	NOUN
dpc-4390	34	3	criteria	criterion	NOUN
dpc-4390	34	4	)	)	PUNCT
dpc-4390	34	5	was	be	AUX
dpc-4390	34	6	considered	consider	VERB
dpc-4390	34	7	grade	grade	NOUN
dpc-4390	34	8	1	1	NUM
dpc-4390	34	9	in	in	ADP
dpc-4390	34	10	5	5	NUM
dpc-4390	34	11	(	(	PUNCT
dpc-4390	34	12	22.7	22.7	NUM
dpc-4390	34	13	%	%	NOUN
dpc-4390	34	14	)	)	PUNCT
dpc-4390	34	15	patients	patient	NOUN
dpc-4390	34	16	and	and	CCONJ
dpc-4390	34	17	grade	grade	NOUN
dpc-4390	34	18	2	2	NUM
dpc-4390	34	19	in	in	ADP
dpc-4390	34	20	3	3	NUM
dpc-4390	34	21	(	(	PUNCT
dpc-4390	34	22	13.6	13.6	NUM
dpc-4390	34	23	%	%	NOUN
dpc-4390	34	24	)	)	PUNCT
dpc-4390	34	25	patients	patient	NOUN
dpc-4390	34	26	at	at	ADP
dpc-4390	34	27	visit	visit	NOUN
dpc-4390	34	28	3	3	NUM
dpc-4390	34	29	(	(	PUNCT
dpc-4390	34	30	table	table	NOUN
dpc-4390	34	31	1	1	NUM
dpc-4390	34	32	)	)	PUNCT
dpc-4390	34	33	.	.	PUNCT
dpc-4390	35	1	approximately	approximately	ADV
dpc-4390	35	2	one	one	NUM
dpc-4390	35	3	-	-	PUNCT
dpc-4390	35	4	third	third	NOUN
dpc-4390	35	5	of	of	ADP
dpc-4390	35	6	patients	patient	NOUN
dpc-4390	35	7	received	receive	VERB
dpc-4390	35	8	emollient	emollient	NOUN
dpc-4390	35	9	treatments	treatment	NOUN
dpc-4390	35	10	during	during	ADP
dpc-4390	35	11	the	the	DET
dpc-4390	35	12	study	study	NOUN
dpc-4390	35	13	(	(	PUNCT
dpc-4390	35	14	table	table	NOUN
dpc-4390	35	15	1	1	NUM
dpc-4390	35	16	)	)	PUNCT
dpc-4390	35	17	.	.	PUNCT
dpc-4390	36	1	hi	hi	INTJ
dpc-4390	36	2	scores	score	NOUN
dpc-4390	36	3	decreased	decrease	VERB
dpc-4390	36	4	,	,	PUNCT
dpc-4390	36	5	with	with	ADP
dpc-4390	36	6	a	a	DET
dpc-4390	36	7	mean	mean	ADJ
dpc-4390	36	8	±	±	NOUN
dpc-4390	36	9	sd	sd	NOUN
dpc-4390	36	10	change	change	NOUN
dpc-4390	36	11	from	from	ADP
dpc-4390	36	12	baseline	baseline	NOUN
dpc-4390	36	13	of	of	ADP
dpc-4390	36	14	–	–	PUNCT
dpc-4390	36	15	5.10	5.10	NUM
dpc-4390	36	16	±	±	NUM
dpc-4390	36	17	17.22	17.22	NUM
dpc-4390	36	18	and	and	CCONJ
dpc-4390	36	19	–	–	PUNCT
dpc-4390	36	20	6.30	6.30	NUM
dpc-4390	36	21	±	±	NUM
dpc-4390	36	22	20.68	20.68	NUM
dpc-4390	36	23	at	at	ADP
dpc-4390	36	24	visits	visit	NOUN
dpc-4390	36	25	2	2	NUM
dpc-4390	36	26	and	and	CCONJ
dpc-4390	36	27	3	3	NUM
dpc-4390	36	28	(	(	PUNCT
dpc-4390	36	29	table	table	NOUN
dpc-4390	36	30	1	1	NUM
dpc-4390	36	31	)	)	PUNCT
dpc-4390	36	32	.	.	PUNCT
dpc-4390	37	1	research	research	NOUN
dpc-4390	37	2	letter	letter	NOUN
dpc-4390	37	3	|	|	ADV
dpc-4390	37	4	dermatol	dermatol	ADJ
dpc-4390	37	5	pract	pract	NOUN
dpc-4390	37	6	concept	concept	NOUN
dpc-4390	37	7	.	.	PUNCT
dpc-4390	38	1	2024;14(4):e2024259	2024;14(4):e2024259	NUM
dpc-4390	38	2	3	3	NUM
dpc-4390	38	3	conclusions	conclusion	NOUN
dpc-4390	38	4	although	although	SCONJ
dpc-4390	38	5	small	small	ADJ
dpc-4390	38	6	and	and	CCONJ
dpc-4390	38	7	without	without	ADP
dpc-4390	38	8	a	a	DET
dpc-4390	38	9	control	control	NOUN
dpc-4390	38	10	group	group	NOUN
dpc-4390	38	11	,	,	PUNCT
dpc-4390	38	12	this	this	DET
dpc-4390	38	13	pilot	pilot	NOUN
dpc-4390	38	14	study	study	NOUN
dpc-4390	38	15	showed	show	VERB
dpc-4390	38	16	that	that	SCONJ
dpc-4390	38	17	less	less	ADJ
dpc-4390	38	18	than	than	ADP
dpc-4390	38	19	one	one	NUM
dpc-4390	38	20	-	-	PUNCT
dpc-4390	38	21	quarter	quarter	NOUN
dpc-4390	38	22	of	of	ADP
dpc-4390	38	23	patients	patient	NOUN
dpc-4390	38	24	(	(	PUNCT
dpc-4390	38	25	22.7	22.7	NUM
dpc-4390	38	26	%	%	NOUN
dpc-4390	38	27	)	)	PUNCT
dpc-4390	38	28	initiating	initiate	VERB
dpc-4390	38	29	egfris	egfris	NOUN
dpc-4390	38	30	or	or	CCONJ
dpc-4390	38	31	mekis	meki	NOUN
dpc-4390	38	32	developed	develop	VERB
dpc-4390	38	33	xerosis	xerosis	NOUN
dpc-4390	38	34	(	(	PUNCT
dpc-4390	38	35	n=3	n=3	NOUN
dpc-4390	38	36	;	;	PUNCT
dpc-4390	38	37	13.6	13.6	NUM
dpc-4390	38	38	%	%	NOUN
dpc-4390	38	39	)	)	PUNCT
dpc-4390	38	40	or	or	CCONJ
dpc-4390	38	41	experienced	experience	VERB
dpc-4390	38	42	worsening	worsening	NOUN
dpc-4390	38	43	of	of	ADP
dpc-4390	38	44	their	their	PRON
dpc-4390	38	45	pre	pre	ADJ
dpc-4390	38	46	-	-	ADJ
dpc-4390	38	47	existing	existing	ADJ
dpc-4390	38	48	xerosis	xerosis	NOUN
dpc-4390	38	49	(	(	PUNCT
dpc-4390	38	50	n=2	n=2	ADV
dpc-4390	38	51	;	;	PUNCT
dpc-4390	38	52	9.1	9.1	NUM
dpc-4390	38	53	%	%	NOUN
dpc-4390	38	54	)	)	PUNCT
dpc-4390	38	55	.	.	PUNCT
dpc-4390	39	1	the	the	DET
dpc-4390	39	2	incidence	incidence	NOUN
dpc-4390	39	3	of	of	ADP
dpc-4390	39	4	xerosis	xerosis	NOUN
dpc-4390	39	5	in	in	ADP
dpc-4390	39	6	the	the	DET
dpc-4390	39	7	current	current	ADJ
dpc-4390	39	8	study	study	NOUN
dpc-4390	39	9	was	be	AUX
dpc-4390	39	10	broadly	broadly	ADV
dpc-4390	39	11	similar	similar	ADJ
dpc-4390	39	12	than	than	ADP
dpc-4390	39	13	that	that	PRON
dpc-4390	39	14	previously	previously	ADV
dpc-4390	39	15	reported	report	VERB
dpc-4390	39	16	with	with	ADP
dpc-4390	39	17	other	other	ADJ
dpc-4390	39	18	targeted	target	VERB
dpc-4390	39	19	anticancer	anticancer	NOUN
dpc-4390	39	20	therapies	therapy	NOUN
dpc-4390	39	21	(	(	PUNCT
dpc-4390	39	22	20.1%–46.5	20.1%–46.5	NUM
dpc-4390	39	23	%	%	NOUN
dpc-4390	39	24	)	)	PUNCT
dpc-4390	40	1	[	[	X
dpc-4390	40	2	3	3	NUM
dpc-4390	40	3	]	]	PUNCT
dpc-4390	40	4	.	.	PUNCT
dpc-4390	41	1	future	future	ADJ
dpc-4390	41	2	research	research	NOUN
dpc-4390	41	3	on	on	ADP
dpc-4390	41	4	the	the	DET
dpc-4390	41	5	frequency	frequency	NOUN
dpc-4390	41	6	and	and	CCONJ
dpc-4390	41	7	impact	impact	NOUN
dpc-4390	41	8	of	of	ADP
dpc-4390	41	9	xerosis	xerosis	NOUN
dpc-4390	41	10	is	be	AUX
dpc-4390	41	11	warranted	warrant	VERB
dpc-4390	41	12	in	in	ADP
dpc-4390	41	13	a	a	DET
dpc-4390	41	14	larger	large	ADJ
dpc-4390	41	15	cohort	cohort	NOUN
dpc-4390	41	16	of	of	ADP
dpc-4390	41	17	patients	patient	NOUN
dpc-4390	41	18	receiving	receive	VERB
dpc-4390	41	19	egfris	egfris	NOUN
dpc-4390	41	20	or	or	CCONJ
dpc-4390	41	21	mekis	meki	NOUN
dpc-4390	41	22	over	over	ADP
dpc-4390	41	23	a	a	DET
dpc-4390	41	24	prolonged	prolonged	ADJ
dpc-4390	41	25	treatment	treatment	NOUN
dpc-4390	41	26	period	period	NOUN
dpc-4390	41	27	in	in	ADP
dpc-4390	41	28	real	real	ADJ
dpc-4390	41	29	-	-	PUNCT
dpc-4390	41	30	world	world	NOUN
dpc-4390	41	31	clinical	clinical	ADJ
dpc-4390	41	32	practice	practice	NOUN
dpc-4390	41	33	.	.	PUNCT
dpc-4390	42	1	the	the	DET
dpc-4390	42	2	pathogenesis	pathogenesis	NOUN
dpc-4390	42	3	of	of	ADP
dpc-4390	42	4	xerosis	xerosis	NOUN
dpc-4390	42	5	is	be	AUX
dpc-4390	42	6	related	relate	VERB
dpc-4390	42	7	mostly	mostly	ADV
dpc-4390	42	8	to	to	ADP
dpc-4390	42	9	the	the	DET
dpc-4390	42	10	mechanism	mechanism	NOUN
dpc-4390	42	11	of	of	ADP
dpc-4390	42	12	action	action	NOUN
dpc-4390	42	13	of	of	ADP
dpc-4390	42	14	egfris	egfri	NOUN
dpc-4390	42	15	and	and	CCONJ
dpc-4390	42	16	mekis	meki	NOUN
dpc-4390	42	17	,	,	PUNCT
dpc-4390	42	18	since	since	SCONJ
dpc-4390	42	19	inhibition	inhibition	NOUN
dpc-4390	42	20	of	of	ADP
dpc-4390	42	21	egfr	egfr	NOUN
dpc-4390	42	22	signaling	signal	VERB
dpc-4390	42	23	pathway	pathway	NOUN
dpc-4390	42	24	disrupts	disrupt	VERB
dpc-4390	42	25	epidermal	epidermal	ADJ
dpc-4390	42	26	differentiation	differentiation	NOUN
dpc-4390	42	27	and	and	CCONJ
dpc-4390	42	28	homeostasis	homeostasis	NOUN
dpc-4390	42	29	,	,	PUNCT
dpc-4390	42	30	causing	cause	VERB
dpc-4390	42	31	inflammation	inflammation	NOUN
dpc-4390	42	32	,	,	PUNCT
dpc-4390	42	33	ultraviolet	ultraviolet	ADJ
dpc-4390	42	34	sensitivity	sensitivity	NOUN
dpc-4390	42	35	,	,	PUNCT
dpc-4390	42	36	dry	dry	ADJ
dpc-4390	42	37	skin	skin	NOUN
dpc-4390	42	38	,	,	PUNCT
dpc-4390	42	39	and	and	CCONJ
dpc-4390	42	40	alterations	alteration	NOUN
dpc-4390	42	41	to	to	ADP
dpc-4390	42	42	skin	skin	NOUN
dpc-4390	42	43	barrier	barrier	NOUN
dpc-4390	42	44	function	function	NOUN
dpc-4390	43	1	[	[	X
dpc-4390	43	2	5,6	5,6	NUM
dpc-4390	43	3	]	]	X
dpc-4390	43	4	.	.	PUNCT
dpc-4390	44	1	currently	currently	ADV
dpc-4390	44	2	,	,	PUNCT
dpc-4390	44	3	there	there	PRON
dpc-4390	44	4	are	be	VERB
dpc-4390	44	5	no	no	DET
dpc-4390	44	6	guidelines	guideline	NOUN
dpc-4390	44	7	on	on	ADP
dpc-4390	44	8	how	how	SCONJ
dpc-4390	44	9	to	to	PART
dpc-4390	44	10	manage	manage	VERB
dpc-4390	44	11	xerosis	xerosis	NOUN
dpc-4390	44	12	in	in	ADP
dpc-4390	44	13	patients	patient	NOUN
dpc-4390	44	14	receiving	receive	VERB
dpc-4390	44	15	anticancer	anticancer	NOUN
dpc-4390	44	16	treatments	treatment	NOUN
dpc-4390	44	17	,	,	PUNCT
dpc-4390	44	18	but	but	CCONJ
dpc-4390	44	19	an	an	DET
dpc-4390	44	20	algorithm	algorithm	NOUN
dpc-4390	44	21	based	base	VERB
dpc-4390	44	22	on	on	ADP
dpc-4390	44	23	ctcae	ctcae	NOUN
dpc-4390	44	24	grading	grading	NOUN
dpc-4390	44	25	is	be	AUX
dpc-4390	44	26	recommended	recommend	VERB
dpc-4390	44	27	for	for	ADP
dpc-4390	44	28	early	early	ADJ
dpc-4390	44	29	identification	identification	NOUN
dpc-4390	44	30	and	and	CCONJ
dpc-4390	44	31	prevention	prevention	NOUN
dpc-4390	44	32	of	of	ADP
dpc-4390	44	33	xerosis	xerosis	NOUN
dpc-4390	44	34	and	and	CCONJ
dpc-4390	44	35	others	other	NOUN
dpc-4390	44	36	skin	skin	NOUN
dpc-4390	44	37	complications	complication	NOUN
dpc-4390	44	38	[	[	X
dpc-4390	44	39	3	3	NUM
dpc-4390	44	40	]	]	PUNCT
dpc-4390	44	41	.	.	PUNCT
dpc-4390	45	1	use	use	NOUN
dpc-4390	45	2	of	of	ADP
dpc-4390	45	3	moisturizers	moisturizer	NOUN
dpc-4390	45	4	and	and	CCONJ
dpc-4390	45	5	barrier	barrier	NOUN
dpc-4390	45	6	replacement	replacement	NOUN
dpc-4390	45	7	creams	cream	NOUN
dpc-4390	45	8	is	be	AUX
dpc-4390	45	9	essential	essential	ADJ
dpc-4390	45	10	.	.	PUNCT
dpc-4390	46	1	while	while	SCONJ
dpc-4390	46	2	the	the	DET
dpc-4390	46	3	patients	patient	NOUN
dpc-4390	46	4	in	in	ADP
dpc-4390	46	5	the	the	DET
dpc-4390	46	6	current	current	ADJ
dpc-4390	46	7	study	study	NOUN
dpc-4390	46	8	had	have	VERB
dpc-4390	46	9	xerosis	xerosis	NOUN
dpc-4390	46	10	of	of	ADP
dpc-4390	46	11	grade	grade	NOUN
dpc-4390	46	12	1	1	NUM
dpc-4390	46	13	or	or	CCONJ
dpc-4390	46	14	2	2	NUM
dpc-4390	46	15	severity	severity	NOUN
dpc-4390	46	16	,	,	PUNCT
dpc-4390	46	17	its	its	PRON
dpc-4390	46	18	associated	associated	ADJ
dpc-4390	46	19	burden	burden	NOUN
dpc-4390	46	20	should	should	AUX
dpc-4390	46	21	not	not	PART
dpc-4390	46	22	be	be	AUX
dpc-4390	46	23	underestimated	underestimate	VERB
dpc-4390	46	24	.	.	PUNCT
dpc-4390	47	1	prevention	prevention	NOUN
dpc-4390	47	2	,	,	PUNCT
dpc-4390	47	3	early	early	ADJ
dpc-4390	47	4	detection	detection	NOUN
dpc-4390	47	5	,	,	PUNCT
dpc-4390	47	6	and	and	CCONJ
dpc-4390	47	7	treatment	treatment	NOUN
dpc-4390	47	8	of	of	ADP
dpc-4390	47	9	xerosis	xerosis	NOUN
dpc-4390	47	10	should	should	AUX
dpc-4390	47	11	be	be	AUX
dpc-4390	47	12	appropriately	appropriately	ADV
dpc-4390	47	13	considered	consider	VERB
dpc-4390	47	14	.	.	PUNCT
dpc-4390	48	1	acknowledgments	acknowledgment	NOUN
dpc-4390	48	2	:	:	PUNCT
dpc-4390	48	3	we	we	PRON
dpc-4390	48	4	would	would	AUX
dpc-4390	48	5	like	like	VERB
dpc-4390	48	6	to	to	PART
dpc-4390	48	7	thank	thank	VERB
dpc-4390	48	8	simone	simone	PROPN
dpc-4390	48	9	tait	tait	PROPN
dpc-4390	48	10	of	of	ADP
dpc-4390	48	11	springer	springer	NOUN
dpc-4390	48	12	healthcare	healthcare	PROPN
dpc-4390	48	13	communications	communication	NOUN
dpc-4390	48	14	,	,	PUNCT
dpc-4390	48	15	who	who	PRON
dpc-4390	48	16	wrote	write	VERB
dpc-4390	48	17	the	the	DET
dpc-4390	48	18	outline	outline	NOUN
dpc-4390	48	19	and	and	CCONJ
dpc-4390	48	20	subsequent	subsequent	ADJ
dpc-4390	48	21	drafts	draft	NOUN
dpc-4390	48	22	of	of	ADP
dpc-4390	48	23	the	the	DET
dpc-4390	48	24	letter	letter	NOUN
dpc-4390	48	25	.	.	PUNCT
dpc-4390	49	1	medical	medical	ADJ
dpc-4390	49	2	writing	writing	NOUN
dpc-4390	49	3	assistance	assistance	NOUN
dpc-4390	49	4	was	be	AUX
dpc-4390	49	5	funded	fund	VERB
dpc-4390	49	6	by	by	ADP
dpc-4390	49	7	pierre	pierre	PROPN
dpc-4390	49	8	fabre	fabre	PROPN
dpc-4390	49	9	.	.	PUNCT
dpc-4390	50	1	references	reference	NOUN
dpc-4390	50	2	1	1	NUM
dpc-4390	50	3	.	.	PUNCT
dpc-4390	50	4	lacouture	lacouture	PROPN
dpc-4390	50	5	m	m	PROPN
dpc-4390	50	6	,	,	PUNCT
dpc-4390	50	7	sibaud	sibaud	NOUN
dpc-4390	50	8	v.	v.	ADP
dpc-4390	50	9	toxic	toxic	ADJ
dpc-4390	50	10	side	side	NOUN
dpc-4390	50	11	effects	effect	NOUN
dpc-4390	50	12	of	of	ADP
dpc-4390	50	13	targeted	target	VERB
dpc-4390	50	14	therapies	therapy	NOUN
dpc-4390	50	15	and	and	CCONJ
dpc-4390	50	16	immunotherapies	immunotherapy	NOUN
dpc-4390	50	17	affecting	affect	VERB
dpc-4390	50	18	the	the	DET
dpc-4390	50	19	skin	skin	NOUN
dpc-4390	50	20	,	,	PUNCT
dpc-4390	50	21	oral	oral	ADJ
dpc-4390	50	22	mucosa	mucosa	NOUN
dpc-4390	50	23	,	,	PUNCT
dpc-4390	50	24	hair	hair	NOUN
dpc-4390	50	25	,	,	PUNCT
dpc-4390	50	26	and	and	CCONJ
dpc-4390	50	27	nails	nail	NOUN
dpc-4390	50	28	.	.	PUNCT
dpc-4390	51	1	am	be	AUX
dpc-4390	51	2	j	j	PROPN
dpc-4390	51	3	clin	clin	PROPN
dpc-4390	51	4	dermatol	dermatol	NOUN
dpc-4390	51	5	.	.	PUNCT
dpc-4390	52	1	2018;19(suppl	2018;19(suppl	PROPN
dpc-4390	52	2	1):31–9	1):31–9	PROPN
dpc-4390	52	3	.	.	PUNCT
dpc-4390	53	1	doi	doi	NOUN
dpc-4390	53	2	:	:	PUNCT
dpc-4390	53	3	10.1007	10.1007	NUM
dpc-4390	53	4	/	/	SYM
dpc-4390	53	5	s40257	s40257	NOUN
dpc-4390	53	6	-	-	PUNCT
dpc-4390	53	7	018	018	NUM
dpc-4390	53	8	-	-	PUNCT
dpc-4390	53	9	0384	0384	NUM
dpc-4390	53	10	-	-	SYM
dpc-4390	53	11	3	3	NUM
dpc-4390	53	12	.	.	NOUN
dpc-4390	53	13	2	2	NUM
dpc-4390	53	14	.	.	PUNCT
dpc-4390	54	1	robert	robert	PROPN
dpc-4390	54	2	c	c	PROPN
dpc-4390	54	3	,	,	PUNCT
dpc-4390	54	4	soria	soria	PROPN
dpc-4390	54	5	jc	jc	PROPN
dpc-4390	54	6	,	,	PUNCT
dpc-4390	54	7	spatz	spatz	PROPN
dpc-4390	54	8	a	a	PROPN
dpc-4390	54	9	,	,	PUNCT
dpc-4390	54	10	et	et	PROPN
dpc-4390	54	11	al	al	PROPN
dpc-4390	54	12	.	.	PUNCT
dpc-4390	55	1	cutaneous	cutaneous	ADJ
dpc-4390	55	2	side	side	NOUN
dpc-4390	55	3	-	-	PUNCT
dpc-4390	55	4	effects	effect	NOUN
dpc-4390	55	5	of	of	ADP
dpc-4390	55	6	kinase	kinase	NOUN
dpc-4390	55	7	inhibitors	inhibitor	NOUN
dpc-4390	55	8	and	and	CCONJ
dpc-4390	55	9	blocking	block	VERB
dpc-4390	55	10	antibodies	antibody	NOUN
dpc-4390	55	11	.	.	PUNCT
dpc-4390	56	1	lancet	lancet	PROPN
dpc-4390	56	2	oncol	oncol	PROPN
dpc-4390	56	3	.	.	PUNCT
dpc-4390	57	1	2005	2005	NUM
dpc-4390	57	2	;	;	PUNCT
dpc-4390	57	3	6(7):491	6(7):491	NUM
dpc-4390	57	4	-	-	SYM
dpc-4390	57	5	500	500	NUM
dpc-4390	57	6	.	.	PUNCT
dpc-4390	58	1	doi	doi	NOUN
dpc-4390	58	2	:	:	PUNCT
dpc-4390	58	3	10.1016	10.1016	NUM
dpc-4390	58	4	/	/	SYM
dpc-4390	58	5	s1470	s1470	PROPN
dpc-4390	58	6	-	-	PUNCT
dpc-4390	58	7	2045(05)70243	2045(05)70243	NUM
dpc-4390	58	8	-	-	PUNCT
dpc-4390	58	9	6	6	NUM
dpc-4390	58	10	.	.	NOUN
dpc-4390	59	1	3	3	NUM
dpc-4390	59	2	.	.	X
dpc-4390	59	3	valentine	valentine	PROPN
dpc-4390	59	4	j	j	PROPN
dpc-4390	59	5	,	,	PUNCT
dpc-4390	59	6	belum	belum	PROPN
dpc-4390	59	7	vr	vr	PROPN
dpc-4390	59	8	,	,	PUNCT
dpc-4390	59	9	duran	duran	PROPN
dpc-4390	59	10	j	j	PROPN
dpc-4390	59	11	,	,	PUNCT
dpc-4390	59	12	et	et	PROPN
dpc-4390	59	13	al	al	PROPN
dpc-4390	59	14	.	.	PROPN
dpc-4390	59	15	incidence	incidence	NOUN
dpc-4390	59	16	and	and	CCONJ
dpc-4390	59	17	risk	risk	NOUN
dpc-4390	59	18	of	of	ADP
dpc-4390	59	19	xerosis	xerosis	NOUN
dpc-4390	59	20	with	with	ADP
dpc-4390	59	21	targeted	target	VERB
dpc-4390	59	22	anticancer	anticancer	NOUN
dpc-4390	59	23	therapies	therapy	NOUN
dpc-4390	59	24	.	.	PUNCT
dpc-4390	59	25	 	 	SPACE
dpc-4390	60	1	j	j	PROPN
dpc-4390	60	2	am	be	AUX
dpc-4390	60	3	acad	acad	ADJ
dpc-4390	60	4	dermatol	dermatol	NOUN
dpc-4390	60	5	.	.	PUNCT
dpc-4390	61	1	2015;72(4):656	2015;72(4):656	NUM
dpc-4390	61	2	-	-	SYM
dpc-4390	61	3	667	667	NUM
dpc-4390	61	4	.	.	PUNCT
dpc-4390	62	1	doi	doi	NOUN
dpc-4390	62	2	:	:	PUNCT
dpc-4390	62	3	10.1016	10.1016	NUM
dpc-4390	62	4	/	/	SYM
dpc-4390	62	5	j.jaad.2014.12.010	j.jaad.2014.12.010	PROPN
dpc-4390	62	6	.	.	PROPN
dpc-4390	63	1	4	4	X
dpc-4390	63	2	.	.	X
dpc-4390	64	1	lee	lee	PROPN
dpc-4390	64	2	j	j	PROPN
dpc-4390	64	3	,	,	PUNCT
dpc-4390	64	4	lim	lim	PROPN
dpc-4390	64	5	j	j	PROPN
dpc-4390	64	6	,	,	PUNCT
dpc-4390	64	7	park	park	NOUN
dpc-4390	64	8	js	js	PROPN
dpc-4390	64	9	,	,	PUNCT
dpc-4390	64	10	et	et	PROPN
dpc-4390	64	11	al	al	PROPN
dpc-4390	64	12	.	.	PUNCT
dpc-4390	65	1	the	the	DET
dpc-4390	65	2	impact	impact	NOUN
dpc-4390	65	3	of	of	ADP
dpc-4390	65	4	skin	skin	NOUN
dpc-4390	65	5	problems	problem	NOUN
dpc-4390	65	6	on	on	ADP
dpc-4390	65	7	the	the	DET
dpc-4390	65	8	quality	quality	NOUN
dpc-4390	65	9	of	of	ADP
dpc-4390	65	10	life	life	NOUN
dpc-4390	65	11	in	in	ADP
dpc-4390	65	12	patients	patient	NOUN
dpc-4390	65	13	treated	treat	VERB
dpc-4390	65	14	with	with	ADP
dpc-4390	65	15	anticancer	anticancer	NOUN
dpc-4390	65	16	agents	agent	NOUN
dpc-4390	65	17	:	:	PUNCT
dpc-4390	65	18	a	a	DET
dpc-4390	65	19	cross	cross	ADJ
dpc-4390	65	20	-	-	ADJ
dpc-4390	65	21	sectional	sectional	ADJ
dpc-4390	65	22	study	study	NOUN
dpc-4390	65	23	.	.	PUNCT
dpc-4390	66	1	cancer	cancer	NOUN
dpc-4390	66	2	res	re	NOUN
dpc-4390	66	3	treat	treat	NOUN
dpc-4390	66	4	.	.	PUNCT
dpc-4390	67	1	2018;50(4	2018;50(4	NUM
dpc-4390	67	2	):	):	PUNCT
dpc-4390	67	3	1186	1186	NUM
dpc-4390	67	4	-	-	SYM
dpc-4390	67	5	1193	1193	NUM
dpc-4390	67	6	.	.	PUNCT
dpc-4390	68	1	doi	doi	NOUN
dpc-4390	68	2	:	:	PUNCT
dpc-4390	68	3	10.4143	10.4143	NUM
dpc-4390	68	4	/	/	SYM
dpc-4390	68	5	crt.2017.435	crt.2017.435	NOUN
dpc-4390	68	6	.	.	PUNCT
dpc-4390	69	1	5	5	X
dpc-4390	69	2	.	.	X
dpc-4390	69	3	lacouture	lacouture	VERB
dpc-4390	69	4	me	i	PRON
dpc-4390	69	5	.	.	PUNCT
dpc-4390	70	1	mechanisms	mechanism	NOUN
dpc-4390	70	2	of	of	ADP
dpc-4390	70	3	cutaneous	cutaneous	ADJ
dpc-4390	70	4	toxicities	toxicity	NOUN
dpc-4390	70	5	to	to	PART
dpc-4390	70	6	egfr	egfr	VERB
dpc-4390	70	7	inhibitors	inhibitor	NOUN
dpc-4390	70	8	.	.	PUNCT
dpc-4390	70	9	  	  	SPACE
dpc-4390	71	1	nat	nat	PROPN
dpc-4390	71	2	rev	rev	PROPN
dpc-4390	71	3	cancer	cancer	NOUN
dpc-4390	71	4	.	.	PUNCT
dpc-4390	72	1	2006;6(10):803	2006;6(10):803	NOUN
dpc-4390	72	2	-	-	SYM
dpc-4390	72	3	812	812	NUM
dpc-4390	72	4	.	.	PUNCT
dpc-4390	72	5	doi	doi	NOUN
dpc-4390	72	6	:	:	PUNCT
dpc-4390	72	7	10.1038	10.1038	NUM
dpc-4390	72	8	/nrc1970	/nrc1970	SYM
dpc-4390	72	9	.	.	PROPN
dpc-4390	73	1	6	6	NUM
dpc-4390	73	2	.	.	X
dpc-4390	73	3	pastore	pastore	PROPN
dpc-4390	73	4	s	s	PROPN
dpc-4390	73	5	,	,	PUNCT
dpc-4390	73	6	lulli	lulli	PROPN
dpc-4390	73	7	d	d	NOUN
dpc-4390	73	8	,	,	PUNCT
dpc-4390	73	9	girolomoni	girolomoni	ADJ
dpc-4390	73	10	g.	g.	NOUN
dpc-4390	73	11	epidermal	epidermal	ADJ
dpc-4390	73	12	growth	growth	NOUN
dpc-4390	73	13	factor	factor	NOUN
dpc-4390	73	14	receptor	receptor	NOUN
dpc-4390	73	15	signalling	signal	VERB
dpc-4390	73	16	in	in	ADP
dpc-4390	73	17	keratinocyte	keratinocyte	NOUN
dpc-4390	73	18	biology	biology	NOUN
dpc-4390	73	19	:	:	PUNCT
dpc-4390	74	1	implications	implication	NOUN
dpc-4390	74	2	for	for	ADP
dpc-4390	74	3	skin	skin	NOUN
dpc-4390	74	4	toxicity	toxicity	NOUN
dpc-4390	74	5	of	of	ADP
dpc-4390	74	6	tyrosine	tyrosine	NOUN
dpc-4390	74	7	kinase	kinase	PROPN
dpc-4390	74	8	inhibitors	inhibitor	NOUN
dpc-4390	74	9	.	.	PUNCT
dpc-4390	74	10	 	 	SPACE
dpc-4390	74	11	arch	arch	ADJ
dpc-4390	74	12	toxicol	toxicol	NOUN
dpc-4390	74	13	.	.	PUNCT
dpc-4390	74	14	2014	2014	NUM
dpc-4390	74	15	;	;	PUNCT
dpc-4390	74	16	88(6):1189	88(6):1189	NUM
dpc-4390	74	17	-	-	SYM
dpc-4390	74	18	1203	1203	NUM
dpc-4390	74	19	.	.	PUNCT
dpc-4390	75	1	doi	doi	NOUN
dpc-4390	75	2	:	:	PUNCT
dpc-4390	75	3	10.1007	10.1007	NUM
dpc-4390	75	4	/	/	SYM
dpc-4390	75	5	s00204	s00204	NOUN
dpc-4390	75	6	-	-	PUNCT
dpc-4390	75	7	014	014	NUM
dpc-4390	75	8	-	-	PUNCT
dpc-4390	75	9	1244	1244	NUM
dpc-4390	75	10	-	-	PUNCT
dpc-4390	75	11	4	4	NUM
dpc-4390	75	12	.	.	PUNCT